Discovery of Biomarker Signatures Prognostic for Neuropathic Pain after Acute Spinal Cord Injury
Document text
Principal Investigator: Georgene W Hergenroeder Organization: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON Fiscal Year: 2024 Award: $1,401,149 Funding agency: National Institute of Neurological Disorders and Stroke Project Summary/Abstract Debilitating neuropathic pain occurs in 40-70% of people who suffer from spinal cord injury (SCI). It is unknown why, with similar injuries, one person will develop neuropathic pain while another will not. There are no distinguishing characteristics to identify who will develop neuropathic pain. The objective of this research is to develop a biomarker signature prognostic of SCI-induced neuropathic pain. The ultimate goal is to identify new non-addictive treatments for its prevention. R61 Phase Specific Aim 1: To identify autoantibodies (ab) in plasma samples from acute SCI patients to CNS autoantigens and determine the relationship between ab levels to the development of NP. R61 Phase Specific Aim 2: To identify the autoantibody combination with maximal prognostic accuracy for the development of NP at 6 months after SCI. R33 Phase Specific Aim 3: Develop and optimize an assay to simultaneously measure several autoantibodies (to be determined during R61) and independently validate the prognostic efficacy for NP using plasma samples collected prospectively. The research will use banked and prospectively enrolled samples from SCI patients and healthy controls. Subjects' pain phenotypes will be carefully characterized. Techniques capitalizing on antibody-antigen binding will be used to optimize an autoantibody biomarker signature predictive of neuropathic pain. Establishing a panel will refine the prognostic value of these autoantibodies as biomarkers in order to detect those who are vulnerable to developing neuropathic pain with high reliability and may be used to facilitate the future development of non-addictive pain therapeutics. Terms: <2 Dimensional Gel Electrophoresis><2-D Gel Electrophoresis><7S Gamma Globulin><Acute><Antigens><Archives><Area Under Curve><Assay><Astroprotein><Autoantibodies><Autoantigens><Autologous Antigens><Bioassay><Biological Assay><Biological Markers><Blood><Blood Plasma><Blood Reticuloendothelial System><Blood capillaries><CNS Nervous System><CRMP-2 protein><Central Nervous System><Characteristics><Chronic><Classification><Clinical><Clinical Data><Clinical Research><Clinical Study><Development><Diagnostic Findings><Disease><Disorder><Early Diagnosis><Early Intervention><Early treatment><Enrollment><Future><GFA-Protein><GFAP><General Population><General Public><Glial Fibrillary Acid Protein><Glial Fibrillary Acidic Protein><Glial Intermediate Filament Protein><Goals><Human><IgG><Immune system><Immunoblotting><Immunoglobulin G><Individual><Injury><International><Knowledge><Lesion><Light><Logistic Regressions><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measures><Medical Rehabilitation><Medulla Spinalis><Modeling><Modern Man><Molecular><Morbidity><Morbidity - disease rate><Needles><Neuraxis><Neuropathy><Nociceptors><Opiate agonist><Opiate receptor agonist><Opioid agonist><Opioid receptor agonist><Pain><Painful><Patients><Persons><Phase><Phenotype><Photoradiation><Physical activity><Plasma><Plasma Serum><Predictive Value><Prevention><Prognostic Marker><Proteins><QOL><Quality of life><Rank-Sum Tests><Receiver Operating Characteristics><Receiver Operator Characteristics><Refractory><Rehabilitation><Rehabilitation therapy><Research><Reticuloendothelial System, Serum, Plasma><Risk><Rodent Model><SCI Patients><Sampling><Self-Antigens><Sensitivity and Specificity><Signs and Symptoms><Spinal Cord><Spinal Cord Trauma><Spinal Trauma><Spinal cord injured><Spinal cord injury><Spinal cord injury patients><System><Systematics><Techniques><Testing><Therapeutic><Therapeutic Effect><Time><Touch><Touch sensation><Traumatic Myelopathy><Two-Dimensional Gel Electrophoresis><Western Blotting><Western Immunoblotting><Work><adverse consequence><adverse outcome><antibody and antigen binding><autoimmune antibody><autoreactive antibody><bio-markers><biologic marker><biomarker><biomarker array><biomarker discovery><biomarker identification><biomarker panel><biomarker signature><capillary><chronic neuropathic pain><cohort><collapsin response mediator protein-2><conventional therapy><conventional treatment><developmental><early detection><early therapy><enroll><experiment><experimental research><experimental study><experiments><identification of biomarkers><identification of new biomarkers><immunogen><injured><injuries><marker identification><marker panel><neuropathic><neuropathic pain><nociceptive neurons><non-narcotic analgesic><non-opiate analgesic><non-opioid><non-opioid analgesic><non-opioid therapeutics><nonnarcotic analgesics><nonopiate analgesic><nonopioid><nonopioid analgesics><novel><pain scale><pain-sensing neurons><pain-sensing sensory neurons><pain-sensing somatosensory neurons><painful neuropathy><predictive signature><prevent><preventing><prognostic><prognostic ability><prognostic biomarker><prognostic power><prognostic profile><prognostic signature><prognostic utility><prognostic value><prospective><protein blotting><rehab therapy><rehabilitative><rehabilitative therapy><response><self reactive antibody><somatosensory><tactile sensation>